The Biotech Capital Compass
The Biotech Capital CompassBiotechnology & ‘Fog of Valuation’ savant
| Platform |  | Pricing | Freemium | Publishes | Daily |
|---|---|---|---|---|---|
| Issues | 142 | Subscribers | Read | hartajsingh1.substack.com |
Curious about how many subscribers The Biotech Capital Compass has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Video Recap: Drug Development Basics — From Lab Bench to Patients
As the 4Q25 earnings call calendar closes out (with a few micro-cap stragglers stretching into mid-March), attention shifts to the March investor conference run—Leerink, Oppenheimer, Jefferies, and UBS—before medical-meeting season ramps in...
Roche Revisited: The Core Holding Case, Re-scored
Following our AI-generated Video Recap of the February 2025 note, we run a scorecard on FY25 delivery, forward estimates, the next catalyst window, and why CHF exposure matters for US holders.
Video Companion: mRNA Recalibration + AI in Biotech
In this free Video Companion, we revisit two technology narratives that defined biotech’s last few years—and ask what remains once the hype compresses into reality. Part 2 reframes mRNA after the pandemic: not as a broken promise, but as a ...
The Deal Window: Eikon Therapeutics — Valuation, Probability, and the Cost of Time
Part 3: Translating Eikon’s setup into investor math: time, probability, peak sales, and the optionality (and skepticism) embedded in platform credit.
Similar Newsletters
Other publications recommended by the authors of this newsletter.
Authors
The writers behind this newsletter.
Biotech analyst and investor with deep experience across science, strategy, and capital markets. I write to make the sector more understandable, more rigorous, and more human.
Frequently Asked Questions
How can I access the email archive for The Biotech Capital Compass?
You can find recent issues that have been published by The Biotech Capital Compass on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does The Biotech Capital Compass have?
To see how many people subscribe to The Biotech Capital Compass, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in The Biotech Capital Compass?
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Biotech Capital Compass as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like The Biotech Capital Compass?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Biotech Capital Compass using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to The Biotech Capital Compass?
Scroll up to where it says Similar Newsletters to see other publications like The Biotech Capital Compass. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact The Biotech Capital Compass?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.